A North Shore biotech company is reporting encouraging early clinical results for a new COVID-19 treatment that targets the disease’s inflammatory process.

CytoAgents Inc. on Wednesday said the first people who received the company’s drug — dubbed GP1681 — did not have serious reactions in the earliest phase of testing, which generally involves dozens of healthy adults. The Food and Drug Administration requires three phases of testing, with an increasing number of test subjects in later phases to demonstrate safety and efficacy.

Marketing of the new treatment is anticipated by 2022, and CEO Teresa Whalen estimated the cost would be a couple of hundred dollars a dose.

“We are on one important mission to save lives,” she said. “The time is now. Our drug is oral, cost-effective, stable with a long-standing safety record.”

Advertise with us

CytoAgents began phase one clinical trials in Australia in October with contract research organization Novotech and clinical trial unit CMAX Clinical Research. Announcement of progress on the new treatment came the same day Gov. Tom Wolf tested positive for the highly infectious disease and 8,703 new cases were reported in the state.

With the new cases, Pennsylvania’s total to date reached 445,317 cases as the state Department of Health finalizes plans to distribute the first shipments of the COVID-19 vaccine. The plan is expected to be released by the end of the week, a spokeswoman said.

Before the pandemic outbreak, CytoAgents received $100,000 in seed money from Innovation Works, a nonprofit North Shore agency that is supported by government funding to help fledgling businesses grow and create jobs. Innovation Works is also helping CytoAgents secure wet lab space for research.

Moreover, CytoAgents received a $1.3 million Small Business Innovation Research grant from the National Institutes of Health in May to help get the company’s drug to market.

In the focus on new drug development for COVID-19, older effective drugs may be overlooked, said Hooman Noorchashm, a Philadelphia area immunologist who is not involved with the company.

Advertise with us

Targeting COVID-19’s inflammatory reaction in treating the disease would likely save lives, he said. But he worried that a generic alternative drug may be overlooked as an effective treatment.

Cyclosporine, for example, which Dr. Thomas Starzl used to revolutionize organ transplantation at the University of Pittsburgh, is available for as little as $12 a dose for people with health insurance, said Dr. Noorchashm, who has been pressing for expanded testing of cyclosporine as a COVID-19 treatment.

“It’s true, we’re at an inflection point in how we understand how these viruses are killing people,” he said. “In general, focusing on anti-inflammatory treatment is very important, but why are we jumping to the more expensive drugs when we have a generic drug” that costs less?

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699.

This story was originally published with images that are no longer available.